Radie Robert S reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. director Robert S. Radie received an award of 9,633 shares of common stock as a grant of restricted stock units, with no cash paid per share. Following this grant, he beneficially owns 23,985 shares directly.
The restricted stock units vest on July 1, 2027, subject to his continued service through the company’s 2027 annual meeting. The company also implemented a 1-for-10 reverse stock split effective July 1, 2026, and Radie’s reported shareholdings and equity awards have been adjusted to reflect this split.
COOPER JOHN G reported acquisition or exercise transactions in this Form 4 filing.
Rockwell Medical director John G. Cooper received an equity award rather than buying shares on the market. On July 1, 2026, he was granted 9,633 restricted stock units of common stock at no cash cost as compensation.
The RSUs vest on July 1, 2027, subject to his continued service through the 2027 Annual Meeting. Effective at 12:01 a.m. on July 1, 2026, Rockwell Medical implemented a 1-for-10 reverse stock split, and Cooper’s equity awards and holdings were proportionally adjusted. Following these adjustments and the reported grant, he beneficially owns 23,670 shares of common stock directly.
Chole Timothy reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. granted SVP and CCO Timothy Chole 15,000 shares of Common Stock as a compensation award, recorded at $0.00 per share. These restricted stock units vest in three equal installments on the first, second and third anniversaries of July 1, 2026, contingent on his continued service.
The company effected a 1-for-10 reverse split of its common stock effective at 12:01 AM on July 1, 2026. Following the grant and split adjustment, Chole beneficially owns 27,285 shares of Rockwell Medical common stock directly.
Hunter Heather reported acquisition or exercise transactions in this Form 4 filing.
Rockwell Medical Chief Operating Officer Heather Hunter reported receiving an award of 15,000 shares of common stock as compensation, at a stated price of $0.00 per share. Following this grant, she directly holds 28,007 shares of the company’s stock.
Footnotes explain that these are restricted stock units that vest in three equal installments on the first, second and third anniversaries of July 1, 2026, as long as she continues serving the company. The company also effected a 1-for-10 reverse stock split effective just after midnight on July 1, 2026, and her reported post-transaction holdings reflect this adjustment to both shares and outstanding equity awards.
TIMMINS MEGAN C. reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. executive Megan C. Timmins, EVP, CLO & Secretary, received a grant of 15,000 shares of common stock as restricted stock units at no cash cost. These RSUs vest in three equal installments on the first, second and third anniversaries of July 1, 2026, contingent on her continued service.
The filing also notes a 1-for-10 reverse stock split effective at 12:01 AM on July 1, 2026, which reduced her share count and adjusted outstanding equity awards. Following the grant and split adjustment, she beneficially owns 31,240 shares of common stock directly.
Neri Jesse reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. SVP and CFO Jesse Neri received a grant of 15,000 shares of common stock as a stock award, rather than an open-market purchase, at a stated price of $0.00 per share. These restricted stock units vest in three equal installments on the first, second and third anniversaries of July 1, 2026, subject to his continued service to the company.
Effective at 12:01 AM on July 1, 2026, the company completed a 1-for-10 reverse split of its common stock and adjusted outstanding equity awards. After reflecting both the reverse split and this award, Neri directly holds 27,239 shares of Rockwell Medical common stock.
Strobeck Mark reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. reported that President and CEO Mark Strobeck received an award of 30,000 shares of Common Stock as a grant, recorded at a price of $0.00 per share. Following this award, he directly beneficially owns 62,349 shares.
Footnotes explain that the award consists of restricted stock units that vest in three equal installments on the first, second and third anniversaries of July 1, 2026, subject to his continued service. The company also effected a 1-for-10 reverse stock split effective at 12:01 AM on July 1, 2026, which reduced the number of shares held and proportionately adjusted outstanding equity awards, with post-transaction holdings already reflecting this split.
Rockwell Medical, Inc. is implementing a one-for-ten reverse stock split of its common stock. Effective at 12:01 a.m. Eastern Time on July 1, 2026, each ten existing shares will automatically combine into one new share, with no action required from stockholders.
No fractional shares will be issued; instead, holders will receive cash equal to the applicable fraction multiplied by the June 30, 2026 Nasdaq closing price, adjusted for the split. The common stock will continue trading on Nasdaq under the symbol RMTI and will trade on a split-adjusted basis with a new CUSIP. Proportionate adjustments will also be made to equity awards, preferred stock conversion terms and warrants, while authorized capital and par value remain unchanged.
Rockwell Medical, Inc. reported voting results from its 2026 annual shareholder meeting, where stockholders approved all four proposals, including elections, pay, auditor and capital structure changes.
Two Class II directors, Joseph Dawson and Joan Lau, Ph.D., were elected with 9,812,114 and 9,890,379 votes in favor, respectively. Stockholders endorsed executive compensation on an advisory basis with 8,232,918 votes for and ratified EisnerAmper LLP as auditor with 22,996,530 votes for. They also approved an amendment to the Certificate of Incorporation authorizing a reverse stock split of the common stock, with 16,993,038 votes for and 6,597,036 against.
Rockwell Medical, Inc. reported that Nasdaq notified the company on May 8, 2026 that its common stock no longer meets the Nasdaq Capital Market’s Minimum Bid Price Requirement, which requires a minimum closing bid price of $1.00 per share for 30 consecutive business days.
The notice does not immediately affect trading, and the shares will remain listed while Rockwell has 180 calendar days, until November 4, 2026, to regain compliance by having a closing bid price of at least $1.00 for ten consecutive business days. Rockwell has included a proposal for a reverse stock split in its 2026 proxy statement, which it believes could restore compliance if approved and implemented, though it cautions there is no assurance it will regain or maintain compliance or receive additional relief from Nasdaq.